Wellgistics Health Inc. Signs $105,000,000 Letter of Intent to Evaluate Potential Acquisition of Neuritek Therapeutics, Inc. which is Pioneering Innovative Therapies for Neurological and Psychiatric Disorders

Contributed by: ACCESS Newswire

Logo

Tags

Healthcare & Pharmaceutical

NASDAQ:WGRX

Wellgistics Health, Inc.

Company Update

More Like This

Wellgistics Health and Kare PharmTech Execute Joint Venture Expanding Access to 200,000+ Patient Lives

Wellgistics Health Accelerates Digital Health Expansion of its Newly Announced RPM, RTM and CCM Pilot with Planned Acquisition of WellCare Today and its Proprietary Samsung Galaxy Watch Care Monitoring Program

Wellgistics Health Announces Pilot MSO Collaboration with Kare PharmTech Targeting $14 Billion U.S. Market for CCM and RPM Services

Neuraptive Therapeutics, Inc. Announces Key Organizational Updates to Support the Company’s Advancement Toward Commercialization

Synaptiq Therapeutics Launches with Acquisition of Clinical-Stage SYN-001 Program

Neuraptive Therapeutics Inc. Receives Orphan Drug Designation for its Lead Development Asset

NovaGo Therapeutics Closes USD 30 Million Series B Financing to Advance Proof-of-Concept Study in Acute Spinal Cord Injury

Neoclease receives Merck’s North American Advance Biotech Grant.

Merck Announces Neoclease as Winner of 2025 North American Advance Biotech Grant